News


All News

Mt. Laurel, N.J. - The Dermatology Nurses' Association (DNA) is teaming up with international publisher Lippincott, Williams and Wilkins'(LWW) to launch its own journal that will be available in its entirety online, according PR Newswire.

Silver Springs, Md. - An Food and Drug Administration (FDA) panel ruled Johnson & Johnson's experimental drug, ustekinumab, should be approved for treating moderate to severe psoriasis in adults, Reuters reports.

National report - A study published in the June issue of the Archives of Dermatology demonstrate a hair-count method to determine if you're balding, according to HealthDay News.

Scottsdale, Ariz. - Medicis' purchase of LipoSonix, an ultrasound technology used to target fat cells, will launch the company into the international marketplace and the body-contouring business, the East Valley Scottsdale Tribune reports.

Irvine, Calif. - Allergan is planning to file a New Drug Application to the FDA by end of the third quarter of 2008 for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth, according to a press release.

Toronto - Psoriasis presentation in childhood marks a stronger genetic component than when the disease onset occurs in adulthook, according to an expert.

National report - The use of biologics is the focus of new psoriasis and psoriatic arthritis management guidelines released by the American Academy of Dermatology (AAD), HealthDay News reports.

Toronto - A Canadian research team reports that intensity-modulated radiation therapy (IMRT) reduces the incidence of radiation-induced dermatitis, compared to conventional radiation, in women being treated for breast cancer, according to Reuters Health.

Scottsdale, Ariz. - Medicis Pharmaceutical has issued a statement announcing its voluntary recall of lot numbers B080037 and B080038 of the antibiotic Solodyn Extended Release Tablets, 90 mg, 30-count bottles, both of which carry an expiration date of December 2009.

Scottsdale, Ariz. - Medicis Pharmaceutical, based here, has announced that the Food and Drug Administration (FDA) has begun a review of Reloxin, the company’s Botox-like anti-wrinkle injectable, the Arizona Republic reports.

As with any legal or insurance planning, the early bird is richly rewarded. Nowhere in practice planning is this truer than in the Buy-Sell agreement. The reason is not so much economic, but political. If this planning is done before any owner is close to a disability, divorce, retirement, or death, all owners are in the same position relative to each other. That makes the negotiation of a standard deal for all owners a much easier and smoother process. Planning early for a Buy-Sell agreement will truly benefit you, your family and your practice.